Notably, EVA1 expresses highly in GBM-initiating cells (tumorigenic cells resistant to radio- and chemotherapies) and in stem cell marker-expressing cells from GBM tissues, and EVA1 deficiency weakens GBM-initiating cell self-renewal potentials [12]. This evidence concerns the gene MPZL2 and glioblastoma.